Doxorubicin Hydrochloride Injection, Powder, Lyophilized, For Solution
Product Images NDC 70121-1218

Product Visual Gallery

This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Doxorubicin Hydrochloride (NDC 70121-1218). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Amneal Pharmaceuticals Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Formula_ (Doxorubicin Hydrochloride For Injection Usp 1)

Chemical structure of Doxorubicin Hydrochloride, showing its molecular formula C27H29NO11+HCl and molecular weight 579.99.*

FDA Label Image

1 (Doxorubicin Hydrochloride For Injection Usp 2)

A forest plot chart showing hazard ratios with 95% confidence intervals for multiple clinical trials comparing Doxorubicin-based treatments against CMF. The chart lists trials on the vertical axis and hazard ratios on the horizontal axis, indicating whether Doxorubicin is better or worse than CMF. A summary diamond represents the combined result of six studies.*

FDA Label Image

2 (Doxorubicin Hydrochloride For Injection Usp 3)

A forest plot chart comparing hazard ratios from multiple clinical trials related to Doxorubicin Hydrochloride. It shows various study names on the vertical axis and hazard ratios with 95% confidence intervals on the horizontal axis, ranging from 0 to 2. It compares Doxorubicin (DOXO) effectiveness versus comparator treatments (CMP), indicating whether DOXO is better or worse.*

FDA Label Image

1 (Doxorubicin Hydrochloride For Injection Usp 4)

Label for Doxorubicin Hydrochloride for Injection, USP 20 mg/vial, lyophilized powder for intravenous use. The packaging contains 10 single-dose vials. It is marked as a cytotoxic agent with directions to store unconstituted vials at controlled room temperature. Manufactured by Amneal Oncology Pvt. Ltd. and distributed by Amneal Pharmaceuticals LLC.*

FDA Label Image

1 (Doxorubicin Hydrochloride For Injection Usp 5)

Packaging label for Doxorubicin Hydrochloride for Injection, USP 20 mg/vial, lyophilized powder for intravenous use. The label includes dosage strength, single-dose vial designation, cytotoxic agent warning, and storage instructions. Manufactured by Amneal Oncology Pvt. Ltd. and distributed by Amneal Pharmaceuticals LLC. The design is branded with the Amneal logo and includes a barcode and regulatory information.*

FDA Label Image

1 (Doxorubicin Hydrochloride For Injection Usp 6)

Doxorubicin Hydrochloride for Injection, USP 20 mg/vial label for a single-dose vial intended for intravenous use, lyophilized powder for solution. The label states the active ingredient (Doxorubicin HCl, USP 20 mg equivalent to 18.74 mg doxorubicin free base) and excipient (Lactose Monohydrate 100 mg). It notes reconstitution instructions, storage conditions (20 to 25°C, protect from light), warnings about severe cellulitis and tissue necrosis, and manufacturer information (Amneal Oncology Pvt. Ltd., distributed by Amneal Pharmaceuticals LLC). The NDC number 70121-1218-1 is printed on the label.*

FDA Label Image

1 (Doxorubicin Hydrochloride For Injection Usp 7)

Packaging label for Doxorubicin Hydrochloride for Injection, USP 50 mg/vial, lyophilized powder for solution for intravenous use. The label indicates the product is a cytotoxic agent, single-dose vial, manufactured by Amneal Oncology Pvt. Ltd., distributed by Amneal Pharmaceuticals LLC. It includes storage instructions, warnings, and reconstitution directions.*

FDA Label Image

1 (Doxorubicin Hydrochloride For Injection Usp 8)

Label for Doxorubicin Hydrochloride for Injection, USP 50 mg/vial, a lyophilized powder for intravenous injection by Amneal Pharmaceuticals LLC. The single-dose vial contains 50 mg equivalent to 46.86 mg doxorubicin free base and lactose monohydrate 250 mg. Instructions include reconstitution with 25 mL of 0.9% sodium chloride injection, storage at 20° to 25°C, and protection from light. Warning about severe cellulitis, vesication, and tissue necrosis if extravasation occurs is noted.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.